Case Study: University of Washington s Clinical Research Billing Audit Program
|
|
- Jonas Burke
- 6 years ago
- Views:
Transcription
1 Case Study: University of Washington s Clinical Research Billing Audit Program 7 th Annual Conference for Effective Compliance Systems in Higher Education Richard A. Meeks, CCEP
2 Agenda Background Probe Audit Research Billing Audit Program Proposal Research Billing Audit Program Program Results 2
3 Background
4 4
5 Research at Seattle Cancer Care Alliance About 600 studies About 600 study staff Over $1 billion in research $250,000 in Clinical Trials Research 5
6 Medicare regulatory landscape National Coverage Decision (NCD) September 2000 Coverage for Medicare beneficiaries on clinical trials costs beyond usual or conventional care 2005 Rush settles with Federal Government for $1 million. 6
7 Medicare regulatory landscape Medicare Clinical Trials Policy (CTP) October 2007 Affirmed original NCD w/modifications and provided clarification on existing requirements Expanded coverage for studies that are deemed qualified Required identification of all study services that are billed, even usual care Issued new billing codes, January
8 Timeline 2002 Task Force on Billing Compliance in Clinical Trials formed (reported 2003) 2003 Transitional Task Force formed to develop an implementation plan (report 2004) 2005 Clinical Research Budget & Billing Office (CRBB) established, issued policy on Clinical Research Billing which established consistent study budget planning, review and data collection across School of Medicine (SOM) 2006 Probe audit started 8
9 Timeline 2007 Probe audit report issued 2007 Audit program established 2007 Process improvement project implemented to separate study charges from patient charges 2008 Next phase of improvements to implement Medicare s Clinical Trials Policy rolled out 9
10 Key terminology Routine costs Usual care care provided absent study Expanded care administration of the investigational care item, treating complications, monitoring Investigation care item or service under investigation Research costs Items or services provided solely to satisfy data collection and analysis needs Deemed qualified studies Studies sponsored by NIH or other federal agencies (CDC, AHRQ, CMS, DoD, Veterans Affairs) Industry-sponsored drug and device trials 10
11 Clinical Research Billing Risks Compliance Risks Billing non-covered research services to patient/medicare Double billing research services by accepting sponsor funding and billing patient/medicare Other Risks Not billing for all services provided Not including proper coding on routine costs billed to Medicare in conjunction with a clinical trial 11
12 Probe Audit
13 Probe Audit Objectives Policy Compliance Billing Compliance in Clinical Research Policy - April 25, 2005 Consistency in payment terms Research study s: informed consent, protocol, contract, budget, & billing grid Billing performed in accordance with the proposed billing grid Clear documentation of completed coverage analysis 13
14 Probe Audit Scope Facility and professional charges Studies at HMC, SCCA, UWMC Studies had enrolled subjects after 10/1/05 5 studies per entity 3-5 patients per study All billing activity reviewed from 10/1/05 to 9/30/06 14
15 Probe Audit Methodology Studies randomly selected from databases maintained by HSD, OSP, and GCA UWMC & HMC - only one study per department within SOM Included federally & industry funded studies Each study had unique PI Studies included both facility and professional charges where possible 15
16 Sample Size 16 studies reviewed 68 patients were enrolled in 13 studies 30 patient accounts were audited 16
17 Probe Audit Report 15 of 16 studies in compliance with policy One study did not register study subjects All 16 studies had consistent payment terms between informed consent, protocol, contract, budget, and billing grid. 3 of 13 studies billed for clinical services in accordance with the proposed billing grid 3 of 13 studies had clear documentation of coverage analysis 17
18 General Probe Audit Findings 8 studies submitted research charges improperly 14 of 30 patient accounts audited needed to be adjusted Total adjusted charges $12, Improper charges were remediated 18
19 General Probe Audit Findings (cont.) UWMC had two studies in which clinical services were provided, but no billing was found Data collection and retrieval was challenging Multiple resources had to be used to conduct audit (PFS, Medical Records, CDS, Ancillary Services) UWMC unable to obtain patient-specific charges for several ancillary department charges 19
20 Probe Audit Comments & Recommendations Audit Comments Front End & Downstream Processes (Billing and Data Retrieval Issues) - 5 Staff not following procedures or unknown procedures - 5 Billing rules not understood 2 Process Recommendations
21 Identified Next Steps Track management responses to the audit findings Research Billing Audit Program Proposal Hospital Research Services Process Improvement Project Created a Clinical Research Billing Remediation policy 21
22 Research Billing Auditing Program Proposal
23 Research Billing Audit Program Proposal 7FTEs for Compliance Internal Audit Consulting 23
24 Approved 3 FTEs in Compliance $300K budget 24
25 Research Billing Audit Program
26 Scope Ensure that researchers are complying with UW Medicine Policies Billing Compliance in Clinical Research Ensure that subject s research related clinical services are billed appropriately and according to applicable regulations 26
27 Elements of the audits Policy Compliance s Billing Compliance in Clinical Research Consistency in payment terms Research study s consent, contract, & budget Determine whether billing is in accordance with billing plan Review 20% of total study subjects or five subjects, whichever is greater Review billing data from the previous year 27
28 Auditing One Research Study per PI (Based on Risk to the Organization) Studies with a large volume of clinical services in the budget A previous history of compliance concerns Studies expected to have high enrollment No research coordinator or few study personnel associated with study Studies begun prior to April 2005 Implantable device studies 28
29 Department/Division Selection The order in which Departments/Divisions were audited was based on the total award amounts and subjects enrolled 29
30 Consultations for study selection Department/Division Leadership Chair/Chief Director/Administrator Research Billing Audit Work Group 30
31 Department/Division Meeting 1. Clinical Research Billing Audit team meets with Department/Division leadership 2. Audit plan is shared 3. AAA Database (database of all clinical trials) reviewed for possible studies 4. Communication template provided to Chair/Chief to communicate to the PIs who will be audited 31
32 Study Audit Process Communicate/meet with PI and study staff Obtain pertinent study documentation Protocol Consent Billing grid Contract Budget Billing data Subject inventory Audit performed 32
33 Study Audit Process (cont.) Draft report reviewed with PI and study staff Final report provided to Research Coordinator, PI, Entity Compliance Officer, Department/Division Leadership, Ancillary Departments Department is provided summary of all study findings from their department 33
34 Additional Auditing Studies that have an audit finding error rate greater than 10% of billing transactions (line items) undergo a 100% audit of all study subjects patient accounts. (Only the last year of billing data is audited) 34
35 Audit Results Analyzed to Determine: The need for repayments, adjustments, disclosures, policy modifications, procedural changes and/or training Information that will help refine operational processes s comprehensive long-range plan for auditing clinical research billing activities 35
36 Where we started Medicine Allergy & Infectious Diseases Psychiatry and Behavioral Sciences Medicine Gastroenterology Medicine Metabolism, Endocrinology, & Nutrition Radiology Neurology Medicine Oncology (in process) 36
37 Program Results
38 General Observations Studies are not being closed with CRBB Study subjects are not in the CRBB subject inventory Billing plans are not updated when protocols or billing codes change 38
39 Program Reporting Quarterly - Board Compliance Committee Monthly - Clinical Trials Budgeting and Billing Oversight Committee Monthly Research Billing Audit Work Group Biweekly Clinical Trials Biweekly Group 39
40 Program Status Contacted 97 PIs Completed 60 study audits Completed 5 Department/Division Reports Completed 2 Department Memos 40
41 Overall Audit Results Reviewed 2,370 lines of service <1% error rate of patient accounts being billed incorrectly Identified $16,000 of lost revenue through incorrect coding Identified $57,000 of unbilled research services 41
42 Next Steps Review auditing process to gain efficiencies Facility Billing System replacement Modifier Review 42
43 Templates Research Billing Audit Summary Research Billing Audit Monthly Status Report Research Billing Audit Report Division-Department Summary Report Model 43
44 Questions Richard Meeks Compliance
ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationHCCA 13 TH ANNUAL COMPLIANCE INSTITUTE LAS VEGAS, NV APRIL 29, 2009
HCCA 13 TH ANNUAL COMPLIANCE INSTITUTE LAS VEGAS, NV APRIL 29, 2009 MEDICARE COVERAGE ANALYSIS WORKSHOP: THE HOW TO OF MEDICARE COVERAGE IN RESEARCH Suzanne LivPage, J.D. Director, Clinical Research Initiation
More informationEnterprise Research Risk
Enterprise Research Risk Managing All the Moving Parts Erika Stevens, MA, Senior Manager Healthcare Advisory Tina Noonan, MBA,CHRC,CIP Director, Research and Regulatory Affairs Learning objectives Describe
More informationClinical Trials Series Part II
Clinical Trials Series Part II Agenda Recap December Presentation J. Schmelz Example: New CT from HSC Investigator Non Cancer Clinical Trial J. Bates, P. Miranda Example: New CT from External Entity Non
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: clinical_trial_services 3/2002 2/2018 2/2019 8/2018 Description of Procedure or Service Clinical trials are
More informationResearch 101. Health Care Compliance Association Regional Conference Columbus, Ohio May 8, 2015
Research 101 Health Care Compliance Association Regional Conference Columbus, Ohio May 8, 2015 Jennifer Lanter, MSPH, BSN, RN, CCRC Director, Research & Special Billing Office Agenda Research Compliance
More informationRe: NCA Tracking Sheet for Clinical Trial Policy (CAG-00071R)
August 9, 2006 BY ELECTRONIC DELIVERY Steve Phurrough, M.D. Coverage and Analysis Group Centers for Medicare and Medicaid Services Department of Health and Human Services Mailstop: C1-12-28 7500 Security
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationResearch and the EHR: Process Improvement Through Integration
Research and the EHR: Process Improvement Through Integration Session 160, March 8, 2018 Arash Naeim, MD PhD, Chief Medical Research Officer, UCLA Health System Marti Arvin, VP of Audit Strategy, CynergisTek
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationClinical Trial Basics:
Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial
More informationNEUROENDOVASCULAR TRIALS
1 NEUROENDOVASCULAR TRIALS Understanding your Research Role in Stroke and Device Trials Tuesday, June 09, 2015 2 Biography Christy Anton is a Clinical Research Coordinator at Rush University Medical Center.
More informationWork Instruction - Research Billing Risk
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO Work Instruction - Research Billing Risk Velos eresearch Version 9.2 Version: 2.0, 04/03/2015 Revision History Version/Amendment #: Version
More informationSOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018
SOCIETY OF RESEARCH ADMINISTRATORS ORLANDO FLORIDA OCTOBER 2018 CLINICAL TRIALS FINANCIAL MANAGEMENT ADMINISTRATIVE CHALLENGES & CONSIDERATIONS Agenda 1. Introduction 2. Challenges in Clinical Trial Financial
More informationFDA Inspections: FDA Inspections: An Overview Overview
FDA Inspections: An Overview Robert Lindblad, MD The EMMES Corporation August 11, 2011 researchcartoons.com Why Inspections? Why Inspections? To evaluate compliance with regulations To establish that an
More information3.0 HSC Relation to Other KUMC Committees
3.0 HSC Relation to Other KUMC Committees It is the policy of the HSC to work in conjunction with other KUMC Committees to provide protections to research subjects. The HSC coordinates reviews with other
More informationHCCA Research Compliance Conference. June 5-8, 2016
There can be no doubt but that the statutes and provisions in question, involving the financing of Medicare, are among the most completely impenetrable texts within human experience... one approaches [them]
More informationCOOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS
COOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS Table of Contents I. OHRP Guidance on Engagement of Institutions in Human Subjects Research... 2 II. External Investigators: The institution in question
More informationIBM Clinical Trial Management System for Sites
Service Description IBM Clinical Trial Management System for Sites This Service Description describes the Cloud Service IBM provides to Client. Client means the contracting party and its authorized users
More information1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More informationTrends in CMS Audits and Enforcement Actions Against Medicare Advantage and Part D Plans
ATTAC consulting Group LLC Lippincott Law Firm PLLC Trends in CMS Audits and Enforcement Actions Against Medicare Advantage and Part D Plans Anne Crawford, ATTAC Consulting Group LLC Elizabeth Lippincott,
More informationAUDIT UNDP HAITI GRANTS FROM THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA. Report No Issue Date: 15 April 2014
UNITED NATIONS DEVELOPMENT PROGRAMME AUDIT OF UNDP HAITI GRANTS FROM THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA Report No. 1267 Issue Date: 15 April 2014 Table of Contents Executive Summary
More informationNot My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center
Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center Office of Research Compliance and Quality Assurance Yolanda P. Davis Sr. Research Compliance Officer Author: Yolanda P.
More informationA/B =A/B is a subcomponent of X and is the sum of a faculty member s tenure level and other grant and contract funding.
University of Washington Faculty Effort and Cost Share Certification Guidelines for Determining and Adjusting Salary Cap Cost Sharing for UW/VA Appointed Faculty Overview: After careful consideration,
More informationIBM Clinical Trial Management System for Sites
Service Description IBM Clinical Trial Management System for Sites This Service Description describes the Cloud Service IBM provides to Client. Client means the contracting party and its authorized users
More informationCOVERAGE ELIGIBILITY OF SERVICES ASSOCIATED WITH A CLINICAL TRIAL
Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its
More information5/14/2018. Billing and Revenue Integrity How Do We Effectively Audit or Monitor? Today s Agenda. What We Hear as the Revenue Integrity Program Goal
Billing and How Do We Effectively Audit or Monitor? Lori Laubach, CHC Partner Health Care Consulting Today s Agenda Definition of revenue integrity How is the Government looking at revenue integrity? Revenue
More informationNIH Policy on Dissemination of NIH- Funded Clinical Trial Information
NIH Policy on Dissemination of NIH- Funded Clinical Trial Information Valery Gordon, Ph.D., M.P.H. Senior Advisor for Human Subjects Protection Division of Clinical Innovation 2018 Spring CTSA Program
More informationTITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19
POLICY #: MULTI-100 Page: 1 of 4 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center research must comply
More informationJune 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
More informationClinical Research Billing Systems
Clinical Research Billing Systems Internal Audit Report No. I2017-202 January 30, 2017 Prepared By Mike Shead, Senior Auditor Reviewed By Niran Joshi, Associate Director Approved By Mike Bathke, Director
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationSCCA Research Revenue Cycle From Set Up to Invoice
SCCA Research Revenue Cycle From Set Up to Invoice Orientation for Research Study Staff Clinical Research Billing SCCA Training Objectives Understand Key Concepts in SCCA Research Revenue Cycle Patient-Billable
More informationObtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process
Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Helene Orescan, J.D. Bishoy Anastasi, MBA, CCRP David Geffen School of Medicine at UCLA Industry Sponsored
More informationTrends in CMS Audits and Enforcement Actions Against Medicare Advantage and Part D Plans
ATTAC Consulting Group LLC Strategic Health Law Trends in CMS Audits and Enforcement Actions Against Medicare Advantage and Part D Plans Anne Crawford, ATTAC Consulting Group LLC Emily Moseley, Strategic
More informationPrivacy Assessment: Beginning the Process
Privacy Assessment: Beginning the Process Debbie Troklus, Manager (502) 585-7723 debbie.troklus@us.pwcglobal.com Chuck Self ΠωΧ HIPAA Privacy Provisions IIHI vs. PHI Uses and Disclosures Minimum Necessary
More informationManaging a Research Team. Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services
Managing a Research Team Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services vicka@uw.edu, 206-355-5210 PI responsibilities and organizing a research team Hiring research staff Effective
More informationVerifying Compliance Program Effectiveness in Managed Care
1 Verifying Compliance Program Effectiveness in Managed Care Cornelia M. Dorfschmid, Executive Vice President Rita Isnar, Senior Vice President F E B R U A R Y 8, 2 0 1 1 COPYRIGHT 2011. SERVICES, LLC.
More informationHuman Research Protection Program Guidance for Human Research Determination
Human Research Protection Program Guidance for Human Research Determination I.1.A The sole purpose of the Institutional Review Board (IRB), as defined in federal statutes, is the protection of human subjects
More informationR&D Administration Manager. Research and Development. Research and Development. NHS Staff Trust-Wide THIS IS A CONTROLLED DOCUMENT
Document Title: Document Number: Research Protocol Design for Papworth Sponsored Studies SOP019 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by:
More informationICE 2016 Annual Conference Premiere Diamond Sponsor
ICE Premiere Diamond Sponsor ICE would like to recognize and thank the Premiere Diamond Sponsor of this year s conference and the audio podcast for this breakout session: www.medhok.com Compliance & Audit
More informationLast Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Title: Investigational Drug Billing Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 1. PURPOSE: To assure accurate and
More informationInvestigational New Devices
Page 1 of 14 Investigational New Devices I. Purpose This document describes the policies and procedures for conducting studies involving investigational new devices at Stanford Hospital & Clinics (SHC)
More informationCanadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines
Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines 1. Introduction The Canadian Cancer Clinical Trials Network (3CTN) will support a portfolio of academic clinical trials
More informationClinical Trials Office VPR CTO
Clinical Trials Office VPR CTO Velos eresearch Mysti M. Trainer Budget Analyst - Associate Who is the VPR-CTO? Serve Under the Vice President for Research Part of the Research Administration We work closely
More informationPresented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationFederal Register /Vol. 72, No. 136 /Tuesday, July 17, 2007 /
Federal Register /Vol. 72, No. 136 /Tuesday, July 17, 2007 / 447.504 Determination of AMP. (a) AMP means, with respect to a covered outpatient drug of a manufacturer (including those sold under an NDA
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationUC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual Cindy Gates IRB Administration What is the purpose of the INVESTIGATOR MANUAL? The manual is designed
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationBest Practices in Accounting Standard Codification 606
Best Practices in Accounting Standard Codification 606 Presented By: Mayuri Katare Adityavikram Toshniwal Agenda ASC 606 Guidelines Differences between ASC 605 and ASC 606 Update for the industries Top
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH
DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH TITLE: SOP #: QA-706 Page: 1 of 7 Applicable Regulations & Guidelines: 21 CFR 312.60 General Responsibilities of
More informationRESEARCH SUPPORT SERVICES FRAMEWORK. Streamlining the management and governance of R&D studies in the NHS
RESEARCH SUPPORT SERVICES FRAMEWORK Streamlining the management and governance of R&D studies in the NHS Page 1 of 22 Contents 1. INTRODUCTION... 3 How to use this document... 3 Background... 4 Purpose
More informationClinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationTHE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE
THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE Dr John Lim Dr John Lim Chief Executive Officer Health Sciences Authority Singapore 13 October 2006 Ms Chan Cheng
More informationMulti-Site Clinical Trials In The Community
Multi-Site Clinical Trials In The Community Models and Methods: What Works, What Doesn t and Why Alan Keller, M.D., FACP Cancer Care Associates Oklahoma Why Do Research? Strategically Critical May be the
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More informationThe Research Services Organization (RSO) of the Academic Health Center
Annual Report 2005 The Research Services Organization (RSO) of the Academic Health Center A Summary of the Eighth Year of Operations Submitted by: Mark S. Paller, M.D., M.S. Director, Research Services
More informationCancer Prevention & Research Institute of Texas. IA # Internal Audit Report over Communication Report Date: April 30, 2018 Issued: May 25, 2018
IA # 04-18 Internal Audit Report over Communication Report Date: Issued: May 25, 2018 C O N T E N T S Page Internal Audit Report Transmittal Letter To The Oversight Committee.... 1 Background... 2 Audit
More informationHuman Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationA COMPLIANCE SOLUTION DESIGNED TO HELP PLANS MEET CMS REQUIREMENTS
A COMPLIANCE SOLUTION DESIGNED TO HELP PLANS MEET CMS REQUIREMENTS Founded on the Common Conditions, Improvement Strategies, and Best Practices based on 2013 Program Audit Reviews HPMS memo, dated August
More informationEncounter Data User Group. November 21, :00 PM 4:00 PM ET
Encounter Data User Group November 21, 2013 3:00 PM 4:00 PM ET Agenda Purpose Session Guidelines CMS Updates EDS Updates EDS Items EDS Operational Highlights EDS Industry Updates Resources User Group Evaluation
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationHealth Policy Newsletter
Health Policy Newsletter Volume 15 Number 2 June, 2002 Article 9 The Jefferson Health System Expense Management Engagement Scott Orzell* * Cap Gemini Ernst & Young Copyright 2002 by the author. Health
More informationPART 1: REVENUE INTEGRITY PROGRAM DESIGN, PROCESS AND IMPLEMENTATION CAROLINE RADER ZNANIEC OWNER/FOUNDER LUNA HEALTHCARE ADVISORS
1 PART 1: REVENUE INTEGRITY PROGRAM DESIGN, PROCESS AND IMPLEMENTATION CAROLINE RADER ZNANIEC OWNER/FOUNDER LUNA HEALTHCARE ADVISORS AHIA 33 rd Annual Conference September 21-24, 2014 Austin, Texas www.ahia.org
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection
Effective date of version: April 01, 2012 Study Start-Up SS 202.00 STANDARD OPERATING PROCEDURE FOR Investigator Selection Approval: Nancy M. Paris, MS, FACHE President and CEO 08 March 2012 (Signature
More informationHuman Research Protection Program Compliance Plan
Human Research Protection Program Compliance Plan May 1, 2016 Human Research Protections Program e 1313 21 st Ave. South, Room 504, Nashville, Tennessee 37232 4315 e phone 615-322-2918 e fax 615-343-2648
More informationPATIENT BILLING SYSTEM PATIENT BILLING SYSTEM PDF A PATIENT S GUIDE TO BILLING - MYMSK LOGIN PAGE BILLING AND COLLECTIONS POLICY
PDF A PATIENT S GUIDE TO BILLING - MYMSK LOGIN PAGE BILLING AND COLLECTIONS POLICY 1 / 5 2 / 5 3 / 5 patient billing system pdf patients and their families with the most advanced and highest quality care
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationHCCA Compliance Institute
HCCA Compliance Institute Implementing a Clinical Research Compliance Program Kendra Dimond, Partner Epstein Becker & Green Washington, DC 202-861-0900 F. Lisa Murtha, J.D. Chief Audit and Compliance Officer
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationPreparing Your Organization for a Medicare Advantage / Part D Compliance Audit
Preparing Your Organization for a Medicare Advantage / Part D Compliance Audit February 14, 2012 Today s Discussion Topics Introductions 2 CMS Audit Approach The Basics 4 A Deeper Dive 8 What to do when
More informationRegulatory Visits, Audits and Investigations
Regulatory Visits, Audits and Investigations The Role of the Compliance Officer Carole A. Klove, JD, RN, CHRC Juliann Tenney, JD, CHRC Welcome! The content of this presentation does not necessarily represent
More informationClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
More informationImpact of the Stimulus Package on Health IT Marketplace
Impact of the Stimulus Package on Health IT Marketplace Eric G. Brown Vice President, Research Director Forrester Research June 30, 2009 The American Recovery & Reinvestment Act $790 Billion 3 Entire contents
More informationCompliance Action Plan. Target Date. Responsible Parties. See 1 above. Management. 6 Educate staff, physicians and management on proper use of
Compliance General Compliance Training 1 General compliance training for all Department employees and Management on recognizing and reporting potential compliance issues. 2 Educate Department Managers
More informationHuman Research Protection Program Plan
Revised January 19, 2018 Table of Contents Human Research Protection Program Plan HRP-101 1/19/2018 2 of 13 Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationMedical Device Replacements
Medical Device Replacements Compliance Insights for Device Warranty Credits and No Charge Devices Brenda Mickow, Revenue Compliance Officer Jesse Schafer, Explant Control Manager Mayo Clinic 2016 MFMER
More informationFirst Tier, Downstream and Related Entities (FDR) Medicare Compliance Program Guide
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions First Tier, Downstream and Related Entities (FDR) Medicare Compliance Program Guide March 2018 72.03.801.1 B
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More information3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities
More informationINSTITUTION V. IRB RESPONSIBILITIES
INSTITUTION V. A guide for Reviewing s and Relying Institutions using the SMART Agreement or other reliance agreements Institution v. Responsibilities Working Group of the SMART Harmonization Steering
More informationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO AUDIT SERVICES. Outpatient Pharmacy Billing Project #11-018(A) December 2010
, SAN FRANCISCO AUDIT SERVICES Outpatient Pharmacy Billing Project #11-018(A) December 2010 Fieldwork Performed by: Sugako Amasaki, Principle Auditor Reviewed by: Zuleikha Shakoor, Senior Associate Director
More informationICD-10 Readiness and Implementation SCHFMA. Presented by: Christine Kalish, MBA, CMPE Executive Consultant Date: June 1, 2011
ICD-10 Readiness and Implementation SCHFMA Presented by: Christine Kalish, MBA, CMPE Executive Consultant Date: June 1, 2011 2 Agenda ICD 10 - Background and timeline 5010 -Technical aspects of change
More informationCADTH COMMON DRUG REVIEW. Procedure for the CADTH Common Drug Review
CADTH COMMON DRUG REVIEW Procedure for the CADTH Common Drug Review AUGUST 2014 RECORD OF UPDATES TO THE PROCEDURE FOR THE CADTH COMMON DRUG REVIEW Update Original June 2003 1 January 2005 2 July 2005
More informationTITLE: DF/HCC Investigator-Sponsored Multi-Center TrialsResearch POLICY #: MULTI-100 Page: 11 of 54 Effective Date: 8/31/17 1.
POLICY #: MULTI-100 Page: 11 of 54 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center Trialsresearch
More informationDEPARTMENT(S): REVISION #: POLICY #: ALL SPONSORED BY: PREPARED BY: APPROVED BY: DATE ISSUED: EFFECTIVE: DSRIP Compliance Policy Page 1 of 5
DEPARTMENT(S): REVISION #: POLICY #: ALL 01 01 SPONSORED BY: PREPARED BY: APPROVED BY: DATE ISSUED: EFFECTIVE: DSRIP Compliance Committee Melissa DeJohn, DSRIP Compliance Officer DSRIP Compliance Committee
More information3/17/2016. Unleashing the Power of Data Analytics Presented to: 2016 Compliance Institute. Today s Agenda. What Makes CHAN Healthcare Unique
Unleashing the Power of Data Analytics Presented to: 2016 Compliance Institute 2016 CHAN Healthcare 1 Today s Agenda What Makes CHAN Unique Adding Value through Data Analytics Using Data Analytics in the
More informationMMC-Einstein Research IT Forum
MMC-Einstein Research IT Forum June 7, 2017 Harry Shamoon, Associate Dean for Clinical & Translational Research Barrett Katz, Executive Director, Office of Clinical Trials Vic Hatcher, Associate Dean for
More informationRESPONSE TO RFP - Title Page
University of Pennsylvania RESPONSE TO RFP - Title Page Request for Proposal (RFP) Number: 002 Issue Date: July 16, 2008 Proposal Due Date: August 18 2008 Title of RFP: Central Laboratory for a Randomized
More informationInvestigator s Handbook
Page 96 CHAPTER 11 Investigational Drugs, Agents, Biologics, and Devices Investigational Drugs/Investigational Biologics (Test Articles) A new drug/agent or biologic that is used in a clinical investigation.
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-P
Page 1 of 5 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Protocol Review and Monitoring Committee Revision: N/A Revision Date: N/A Functional and Administrative
More informationIBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol
IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol Use this checklist to assemble your request for your institution s IBC to review a specific protocol. If WIRB does not already administer
More informationClinical Trial Disclosure: Current US Situation
Clinical Trial Disclosure: Current US Situation 1 Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
More information